Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 1291583 on Dabigatran Pharmacokinetics
NCT06791187Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verducatib in bronchiectasis, sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of dabigatran in plasma over the time interval from 0 to the last quantifiable data point up to 4 days and Maximum measured concentration of dabigatran in plasma up to 4 days. Started Jan 2025; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06791187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06791187.